Screener
Inhibrx Biosciences, Inc. INBX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Research and development | $25,217 | $36,877 |
| General and administrative | 5,710 | 6,024 |
| Total operating expenses | 30,927 | 42,901 |
| Loss from operations | (30,927) | (42,901) |
| Other income (expense): | ||
| Interest expense | (3,509) | (2,689) |
| Interest income | 1,007 | 2,329 |
| Other income (expense), net | (12) | (50) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s operating income?
- Inhibrx Biosciences, Inc. (INBX) reported operating income of -$30.93M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s operating income changed year-over-year?
- Inhibrx Biosciences, Inc.'s operating income increased by 27.9% year-over-year, from -$42.9M to -$30.93M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s operating income?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s operating income has grown at a -21.5% compound annual growth rate (CAGR), from -$219.22M to -$135.03M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Inhibrx Biosciences, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude